Impact of Blueberries on Uric Acid and Quality of Life

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01532622

Enrollment

Registered

2012-02-14

Start date

2012-01-31

Completion date

2013-10-31

Last updated

2013-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Keywords

Blueberry

Brief summary

The purpose of this study is to determine the impact of blueberries on uric acid in patients with hyperuricemia that are not receiving uric acid pharmacotherapy. The central hypothesis the investigators propose is that daily blueberries added to a pre-existing diet will promote uric acid lowering and improve quality of life without detriment to vital signs.

Interventions

DIETARY_SUPPLEMENTBlueberry Powder

Patients will take 30 grams of blueberry powder daily for up to 30 days

OTHERPlacebo Powder

Patients will take 30 grams of placebo powder daily for up to 30 days.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 88 Years

Healthy volunteers

Yes

Inclusion criteria

* 18 years or older * Uric acid \> 6.0 mg/dL

Exclusion criteria

* Current moderate-to-severe symptomatic gout * Currently receiving gout pharmacotherapy * Current participation in another clinical trial * Documented non-compliance or consistent missed appointments * Women who are pregnant or nursing

Design outcomes

Primary

Measure	Time frame	Description
Change from Baseline and Placebo in Uric Acid Level in Patients Randomized to Treatment Group	Baseline, ~30 days later	Percent change in uric acid level from baseline after 30 days of treatment with blueberry powder. Since this is designed as a crossover trial, baseline could represent uric acid level at the beginning of the study or after at least a 2-week washout period following placebo administration.

Secondary

Measure	Time frame	Description
Blood Pressure	Baseline, ~30 days, ~45 days, ~75 days	Percent change and absolute change of blood pressure from baseline and placebo
Body Weight	Baseline, ~30 days, ~45 days, ~75 days	Percent change and absolute change of body weight from baseline and placebo
Quality of Life	Baseline, ~30 days, ~45 days, ~75 days	Quality of life will be assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026